Oliver Szolar

a:head bio AG engages in the research in as well as development and marketing of products in the pharmaceutical and biotechnology sectors. Its business activities focus on the development of new therapeutics for the treatment of brain disorders based on human cerebral organoids. The company was founded by Oliver Szolar, Jürgen Knoblich, and Madeline Lancaster and is headquartered in Vienna, Austria.

HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation.